An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study

Li et al delineate a novel technique for assessing measurable residual disease (MRD) by the assessment of isolated leukemia stem cells (LSCs). They report that assessment of MRD in LSCs provides a better prediction of outcome than standard multiparameter flow cytometry.

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. 5; pp. 516 - 520
Main Authors Li, Si-Qi, Xu, Lan-Ping, Wang, Yu, Zhang, Xiao-Hui, Chen, Huan, Chen, Yu-Hong, Wang, Feng-Rong, Han, Wei, Sun, Yu-Qian, Yan, Chen-Hua, Lv, Meng, Tang, Fei-Fei, Mo, Xiao-Dong, Liu, Yan-Rong, Liu, Kai-Yan, Chang, Ying-Jun, Huang, Xiao-Jun
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 04.08.2022
Subjects
Flow Cytometry - methods
Humans
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - genetics
Neoplasm Recurrence, Local
Neoplasm, Residual - diagnosis
Prognosis
Prospective Studies
Recurrence
Transplantation, Homologous
Online AccessGet full text

Cover

More Information
Summary:Li et al delineate a novel technique for assessing measurable residual disease (MRD) by the assessment of isolated leukemia stem cells (LSCs). They report that assessment of MRD in LSCs provides a better prediction of outcome than standard multiparameter flow cytometry.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0006-4971
1528-0020
1528-0020
DOI:10.1182/blood.2021014604